InsiderTrades.com logo
The “Perfect Storm” for Gold
From Gold Safe Exchange   |   Ad
Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.
Click here now to download the free Precious Metals Buying Guide!
Arthur M. Krieg net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Arthur Krieg Biography and Net Worth

Insider of Checkmate Pharmaceuticals
Art has worked in the oligonucleotide field since the 1980s. After discovering immune stimulatory CpG DNA in 1994, he co-founded Coley Pharmaceutical Group in 1997 to develop the technology, discovering and taking 4 novel CpG oligonucleotides into clinical development. In 2008, Pfizer acquired Coley and Art became Chief Scientific Officer of Pfizer’s Oligonucleotide Therapeutics Unit until they exited the field in 2011. Art subsequently co-founded RaNA Therapeutics, serving as its CEO through 2013, and served as CSO at Sarepta Therapeutics until July 2014. He co-founded the first antisense journal, Nucleic Acid Therapeutics, and the Oligonucleotide Therapeutic Society, for which he recently served as President. Art received an MD from Washington University and trained in internal medicine at the University of Minnesota and in rheumatology at the NIH before joining the faculty at the University of Iowa, becoming professor of internal medicine. He has published more than 250 scientific papers and is an inventor on >50 issued US patents covering oligonucleotide technologies.

What is Arthur M. Krieg's net worth?

The estimated net worth of Arthur M. Krieg is at least $8.57 million as of June 18th, 2021. Dr. Krieg owns 815,734 shares of Checkmate Pharmaceuticals stock worth more than $8,565,207 as of April 19th. This net worth approximation does not reflect any other assets that Dr. Krieg may own. Learn More about Arthur M. Krieg's net worth.

How old is Arthur M. Krieg?

Dr. Krieg is currently 65 years old. There are 5 older executives and no younger executives at Checkmate Pharmaceuticals. Learn More on Arthur M. Krieg's age.

How do I contact Arthur M. Krieg?

The corporate mailing address for Dr. Krieg and other Checkmate Pharmaceuticals executives is 245 MAIN STREET 2ND FLOOR, CAMBRIDGE MA, 02142. Checkmate Pharmaceuticals can also be reached via phone at 617-682-3625 and via email at [email protected]. Learn More on Arthur M. Krieg's contact information.

Has Arthur M. Krieg been buying or selling shares of Checkmate Pharmaceuticals?

Arthur M. Krieg has not been actively trading shares of Checkmate Pharmaceuticals over the course of the past ninety days. Most recently, on Friday, June 18th, Arthur M. Krieg bought 7,224 shares of Checkmate Pharmaceuticals stock. The stock was acquired at an average cost of $6.04 per share, with a total value of $43,632.96. Following the completion of the transaction, the insider now directly owns 815,734 shares of the company's stock, valued at $4,927,033.36. Learn More on Arthur M. Krieg's trading history.

Arthur M. Krieg Insider Trading History at Checkmate Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/18/2021Buy7,224$6.04$43,632.96815,734View SEC Filing Icon  
3/25/2021Buy10,036$12.35$123,944.60743,227View SEC Filing Icon  
1/27/2021Buy1,701$13.05$22,198.05733,191View SEC Filing Icon  
1/19/2021Buy500$13.09$6,545.00731,490View SEC Filing Icon  
12/29/2020Buy443$14.16$6,272.88730,990View SEC Filing Icon  
12/15/2020Buy42$14.49$608.58720,639View SEC Filing Icon  
See Full Table

Arthur M. Krieg Buying and Selling Activity at Checkmate Pharmaceuticals

This chart shows Arthur M Krieg's buying and selling at Checkmate Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Checkmate Pharmaceuticals Company Overview

Checkmate Pharmaceuticals logo
Checkmate Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing novel therapeutics for the treatment of cancer. It develops CMP-001, which is in phase II clinical trial in combination with pembrolizumab to treat patients with PD-1 refractory melanoma; combination with nivolumab to treat patients with PD-1 naïve neoadjuvant melanoma; and treatment in patients with PD-1 refractory melanoma. Checkmate Pharmaceuticals, Inc. has strategic alliances with Merck KGaA and Pfizer. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $10.50
Low: $10.50
High: $10.50

50 Day Range

MA: $10.46
Low: $10.37
High: $10.50

2 Week Range

Now: $10.50
Low: $2.00
High: $10.50

Volume

N/A

Average Volume

142,261 shs

Market Capitalization

$231.40 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A
The “Perfect Storm” for Gold
From Gold Safe Exchange   |   Ad
Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.
Click here now to download the free Precious Metals Buying Guide!